Dengue (tetravalent) vaccine is under clinical development by Panacea Biotec and currently in Phase II for Dengue Fever. According to GlobalData, Phase II drugs for Dengue Fever have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dengue (tetravalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dengue (tetravalent) vaccine overview
Vaccine is under development for the prevention of dengue in adult and pediatrics. The therapeutic candidate is a recombinant lyophilized live attenuated vaccine which is formulated as a solution and administered through subcutaneous route. It is a recombinant chimeric tetravalent dengue vaccine.
Panacea Biotec overview
Panacea Biotec (Panacea) is a research-based health management company that research, develops, manufactures, distributes and markets pharmaceuticals, vaccines and biosimilars. Its vaccines portfolio includes trivalent and bivalent oral polio vaccine, and vaccines for diphtheria, tetanus, pertussis, Hepatitis B and haemophilus influenzae Type B. Its pharmaceutical formulations span across therapeutic areas, including oncology, nephrology, orthopedics, gastroenterology, pain management, diabetes, blood-related and organ transplantation, among others. The company also offers contract research and manufacturing services. Panacea operates manufacturing facilities in Baddi, Himachal Pradesh and Lalru, Punjab. It has presence in India, Switzerland, and Germany. Panacea is headquartered in New Delhi, India.
For a complete picture of Dengue (tetravalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
